156 related articles for article (PubMed ID: 38689836)
1. The 10-Year Effects of Intensive Lifestyle Intervention on Kidney Outcomes.
Lavenburg LU; Schaubel DE; Chao AM; Reese PP; Cohen JB
Kidney Med; 2024 May; 6(5):100814. PubMed ID: 38689836
[TBL] [Abstract][Full Text] [Related]
2. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
3. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.
; Gregg EW; Jakicic JM; Blackburn G; Bloomquist P; Bray GA; Clark JM; Coday M; Curtis JM; Egan C; Evans M; Foreyt J; Foster G; Hazuda HP; Hill JO; Horton ES; Hubbard VS; Jeffery RW; Johnson KC; Kitabchi AE; Knowler WC; Kriska A; Lang W; Lewis CE; Montez MG; Nathan DM; Neiberg RH; Patricio J; Peters A; Pi-Sunyer X; Pownall H; Redmon B; Regensteiner J; Rejeski J; Ribisl PM; Safford M; Stewart K; Trence D; Wadden TA; Wing RR; Yanovski SZ
Lancet Diabetes Endocrinol; 2016 Nov; 4(11):913-921. PubMed ID: 27595918
[TBL] [Abstract][Full Text] [Related]
4. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Within and post-trial effects of an intensive lifestyle intervention on kidney disease in adults with overweight or obesity and type 2 diabetes mellitus: a secondary analysis of the Look AHEAD clinical trial.
Knowler WC; Chen H; Bahnson JL; Kahn SE; Lewis CE; Nathan DM; Nelson RG; Pilla SJ; Bantle JP;
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816203
[TBL] [Abstract][Full Text] [Related]
7. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
[TBL] [Abstract][Full Text] [Related]
8. Effect of an Intensive Weight-Loss Lifestyle Intervention on Kidney Function: A Randomized Controlled Trial.
Díaz-López A; Becerra-Tomás N; Ruiz V; Toledo E; Babio N; Corella D; Fitó M; Romaguera D; Vioque J; Alonso-Gómez ÁM; Wärnberg J; Martínez JA; Serra-Majem L; Estruch R; Tinahones FJ; Lapetra J; Pintó X; Tur JA; López-Miranda J; Cano Ibañez N; Delgado-Rodríguez M; Matía-Martín P; Daimiel L; de Paz JA; Vidal J; Vázquez C; Ruiz-Canela M; Bulló M; Sorlí JV; Goday A; Fiol M; García-de-la-Hera M; Tojal Sierra L; Pérez-Farinós N; Zulet MÁ; Sánchez-Villegas A; Sacanella E; Fernández-García JC; Santos-Lozano JM; Gimenez-Gracia M; Del Mar Bibiloni M; Diez-Espino J; Ortega-Azorin C; Castañer O; Morey M; Torres-Collado L; Sorto Sanchez C; Muñoz MÁ; Ros E; Martinez-Gonzalez MA; Salas-Salvadó J;
Am J Nephrol; 2021; 52(1):45-58. PubMed ID: 33556935
[TBL] [Abstract][Full Text] [Related]
9. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial.
Look AHEAD Research Group
Lancet Diabetes Endocrinol; 2014 Oct; 2(10):801-9. PubMed ID: 25127483
[TBL] [Abstract][Full Text] [Related]
10. Associations of Intensive Lifestyle Intervention in Type 2 Diabetes With Health Care Use, Spending, and Disability: An Ancillary Study of the Look AHEAD Study.
Huckfeldt PJ; Frenier C; Pajewski NM; Espeland M; Peters A; Casanova R; Pi-Sunyer X; Cheskin L; Goldman DP
JAMA Netw Open; 2020 Nov; 3(11):e2025488. PubMed ID: 33231638
[TBL] [Abstract][Full Text] [Related]
11. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial.
Pandey A; Patel KV; Bahnson JL; Gaussoin SA; Martin CK; Balasubramanyam A; Johnson KC; McGuire DK; Bertoni AG; Kitzman D; Berry JD;
Circulation; 2020 Apr; 141(16):1295-1306. PubMed ID: 32134326
[TBL] [Abstract][Full Text] [Related]
12. Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes.
Ku E; McCulloch CE; Copeland TP; Inker LA; Tighiouart H; Sarnak MJ
Am J Kidney Dis; 2023 Oct; 82(4):454-463. PubMed ID: 37269972
[TBL] [Abstract][Full Text] [Related]
13. Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression.
Neuen BL; Weldegiorgis M; Herrington WG; Ohkuma T; Smith M; Woodward M
Am J Kidney Dis; 2021 Sep; 78(3):350-360.e1. PubMed ID: 33895181
[TBL] [Abstract][Full Text] [Related]
14. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
[TBL] [Abstract][Full Text] [Related]
15. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
[TBL] [Abstract][Full Text] [Related]
17. Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus.
Zu C; Liu M; Wang G; Meng Q; Gan X; He P; Zhou C; Ye Z; Wei Y; Su X; Zhang Y; Qin X
Diabetes Obes Metab; 2024 Jun; ():. PubMed ID: 38853714
[TBL] [Abstract][Full Text] [Related]
18. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
[TBL] [Abstract][Full Text] [Related]
19. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
